vorinostat
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sickle Cell Disease
Conditions
Sickle Cell Disease, Sickle Cell Anemia
Trial Timeline
Oct 1, 2009 → Oct 1, 2014
NCT ID
NCT01000155About vorinostat
vorinostat is a phase 2 stage product being developed by Merck for Sickle Cell Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT01000155. Target conditions include Sickle Cell Disease, Sickle Cell Anemia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (17)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01365065 | Phase 2 | UNKNOWN |
| NCT01319383 | Phase 1/2 | Completed |
| NCT00918489 | Phase 2 | Completed |
| NCT01000155 | Phase 2 | Terminated |
| NCT00821951 | Phase 1 | Completed |
| NCT00831493 | Phase 1/2 | Terminated |
| NCT00875056 | Phase 2 | Completed |
| NCT00735826 | Pre-clinical | Completed |
| NCT00838929 | Phase 1 | Completed |
| NCT00719875 | Phase 1 | Completed |
| NCT00771472 | Phase 1 | Completed |
| NCT00776503 | Phase 1/2 | Completed |
| NCT00561418 | Phase 1 | Completed |
| NCT00416130 | Phase 1/2 | UNKNOWN |
| NCT00907738 | Phase 2 | Completed |
| NCT00127127 | Phase 1 | Completed |
| NCT00127140 | Phase 1 | Completed |
Competing Products
20 competing products in Sickle Cell Disease